검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Capecitabine/Paclitaxel/Albumin Paclitaxel (Chemotherapy drug, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)) Chia Tai Tianqing Pharmaceutical G…·Breast Cancer ORR 60.4% |
|---|---|
Overview Program | Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) |
Overview Company | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Biomarker | biomarkers including accumulation of iron and 4-hydroxynonenal (4-HNE) via reducing Kelch-like ECH-associated |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Supercritical CO 2 Antisolvent-Micronised Naringin and Naringenin Alleviate Paclitaxel-Induced Pain Syndrome.. Background / Objectives : Paclitaxel is a chemotherapy drug used to treat various tumours, but its use is often limited by an acute and chronic pain syndrome that is poorly managed. Naringin and its aglycone, naringenin, exhibit antioxidant, antitumour, anti-inflammatory, and antinocicept… |
Clinical Primary efficacy | ORR 60.4% |
Clinical ORR | 65.8% |
Clinical PFS | 13.2 |
Clinical OS | 28.9 |
Clinical Result source | ClinicalTrials.gov NCT04494425 |
Clinical Data Tier / Score | A · 72 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Capecitabine/Paclitaxel/Albumin Paclitaxel (Chemotherapy drug, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)) Chia Tai Tianqing Pharmaceutical G…·Breast Cancer ORR 60.4% |
|---|---|
Overview Program | Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel) |
Overview Company | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Overview Modality | ADC |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Biomarker | biomarkers including accumulation of iron and 4-hydroxynonenal (4-HNE) via reducing Kelch-like ECH-associated |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | Supercritical CO 2 Antisolvent-Micronised Naringin and Naringenin Alleviate Paclitaxel-Induced Pain Syndrome.. Background / Objectives : Paclitaxel is a chemotherapy drug used to treat various tumours, but its use is often limited by an acute and chronic pain syndrome that is poorly managed. Naringin and its aglycone, naringenin, exhibit antioxidant, antitumour, anti-inflammatory, and antinocicept… |
Clinical Primary efficacy | ORR 60.4% |
Clinical ORR | 65.8% |
Clinical PFS | 13.2 |
Clinical OS | 28.9 |
Clinical Result source | ClinicalTrials.gov NCT04494425 |
Clinical Data Tier / Score | A · 72 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 4일 (9일 전) |
추천 비교
추천 비교